

SEP. 17. 2009 5:19PM

ENZO BIOCHEM

RECEIVED
CENTRAL FAX CENTER

NO. 8219 P. 14

SEP 17 2009

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Elazar Rabbani et al.)	
)	
Serial No. 10/693,481)	Group Art Unit: 1637
)	
Filed: October 24, 2003)	Exam'r: Angela Marie Bertagna
)	
Title: NOVEL COMPOSITIONS AND METHODS FOR)	
FOR CONTROLLING THE EXTENDABILITY)	
OF VARIOUS COMPONENTS USED IN)	
COPYING OR AMPLIFICATION STEPS)	

527 Madison Avenue (9th Floor)
New York, NY 10022-4304
June 19, 2009

FILED BY EXPRESS MAIL
-- RETURN RECEIPT REQUESTED

Mail Stop – Non-Fee Amendment
Director of Patents
P. O. Box 1450
Alexandria, VA 22313-1450

COMMUNICATION TO SUBMIT
INFORMATION DISCLOSURE STATEMENT BY APPLICANT
(CONCURRENTLY FILED WITH APPLICANTS' REPLY TO SEPTEMBER 15, 2009 NOTICE OF
NON-COMPLIANT AMENDMENT UNDER 37 C.F.R. §1.121)

Dear Sirs:

This paper (Communication To Submit Information Disclosure Statement By Applicants) is being concurrently filed with their Reply To September 15, 2009 Notice of Non-Compliant Amendment Under 37 C.F.R. §1.121. No extension fee is due for the Reply which is being timely filed. Accordingly, this paper (Communication To Submit IDS) is also being timely filed.

Enz-60(CIP)

SEP. 17. 2009 5:20PM

ENZO BIOCHEM


RECEIVED
CENTRAL FAX CENTER

NO. 8219 P. 15

Elazar Rabbani et al.
Serial No.: 11/444,151
Filed: May 31, 2006

SEP 17 2009

Page 2 [Communication To Submit IDS By Applicant (Concurrently Filed With Applicants' Reply To The September 15, 2009 Notice of Non-Compliant Amendment Under 37 C.F.R. §1.121) – September 17, 2009]

CERTIFICATE OF TRANSMISSION	
I hereby certify that this paper (Communication To Submit Information Disclosure Statement By Applicant) (along with any documents referred to as attached or enclosed) is being facsimile transmitted to the United States Patent and Trademarks (Fax No. 571-273-8300) on September 17, 2009.	
SEPT 17 2009 Date	 Ronald C. Fedus Reg. No. 32,567

REMARKS

In this paper, Applicants are submitting their Information Disclosure Statement as evidenced by the single sheet [Form PTO/SB/08A (01-08)] and a single listed document on provided herewith.

Listed on Form PTO/SB/08A (01-08) is U.S. Patent No. 5,853,993 (Dellinger et al.).

It is respectfully requested that the listed U.S. Patent No. 5,853,993 be made of record in this application and that the Examiner consider this document in determining whether to allow any claims in this application.

In the event that any other fee or fees are due in connection with this paper and filing, The Patent and Trademark Office is hereby authorized to charge the amount of any such fee or fees to Deposit Account No. 05-1135, or to credit any overpayment thereto.

If a telephone conversation would further the prosecution of the present application, Applicants' undersigned attorney requests that he be contacted at

Enz-60(CIP)

Elazar Rabbani et al.

Serial No.: 11/444,151

Filed: May 31, 2006

Page 3 [Communication To Submit IDS By Applicant (Concurrently Filed With Applicants' Reply To The September 15, 2009 Notice of Non-Compliant Amendment Under 37 C.F.R. §1.121] – September 17, 2009

the number provided below.

Respectfully submitted,



Ronald C. Fedus

Registration No. 32,567

Attorney for Applicants

ENZO LIFE SCIENCES, INC.

c/o Enzo Biochem, Inc.

527 Madison Avenue, 9th Floor

New York, New York 10022

Telephone: (212) 583-0100

Facsimile: (212) 583-0150

Enz-60(CIP)